#United States #NASDAQ #Intensity Therapeutics #Shelton #INT230-6

Intensity Therapeutics Secures Nasdaq Extension for Compliance

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company focused on cancer therapies, has recently announced a significant development. The firm has received a 180-day extension from The Nasdaq Stock Market to comply with the listing requirements regarding minimum bid price. This extension, granted after the initial period expired on December 3, 2025, represents a critical window for Intensity as it seeks to maintain its listing on Nasdaq under the symbol 'INTS'.

Understanding the Extension

Following the Nasdaq Listing Rule 5550(a)(2), companies must maintain a minimum closing bid price of $1.00 per share for a minimum of ten consecutive business days to remain listed. The board's decision to extend the compliance period until June 1, 2026, underscores the company's proactive strategies aimed at meeting these vital market requirements. Intensity Therapeutics plans to monitor the performance of its stock closely throughout this period, employing all appropriate measures to regain compliance.

About Intensity Therapeutics

Founded with the mission to redefine cancer treatment paradigms, Intensity Therapeutics is harnessing the potential of its proprietary non-covalent conjugation technology to develop innovative treatments targeting solid tumors. Their flagship product, INT230-6, is a groundbreaking intra-tumoral therapy that utilizes a unique formulation designed to penetrate tumor environments effectively. This therapy combines two powerful anti-cancer drugs, cisplatin and vinblastine sulfate, with a diffusion enhancer to facilitate their uptake by tumor cells.

Since its inception, Intensity has made strides in clinical research, having completed two major studies that collectively enrolled over 200 patients. Among these is the Phase 1/2 dose escalation study for metastatic cancers, and the Phase 2 randomized clinical trial aimed at locally advanced breast cancer, showcasing promising results and potential in altering the treatment landscape for malignancies resistant to traditional therapies.

Future Prospects

The ability of INT230-6 to induce tumor cell death and trigger an adaptive immune response positions it as a promising contender for revolutionizing cancer treatment. The company is actively pursuing a Phase 3 trial specifically for soft tissue sarcoma, indicating aggressive steps toward bringing its innovative therapies to market. In addition, the collaboration with the Swiss Cancer Group for the ongoing Phase 2 study represents a strategic move to broaden its reach and impact in cancer research.

Despite the challenges faced in the market, including the compliance issue with Nasdaq, Intensity Therapeutics remains steadfast in its commitment to improving outcomes for cancer patients. They have expressed confidence in overcoming the current hurdles, leveraging their scientific advancements and fostering continuous engagement with investors and stakeholders.

Conclusion

The extension granted by Nasdaq is not just a lifeline for Intensity Therapeutics, but also an affirmation of the company's potential in the competitive field of cancer therapy. As the company looks to regain compliance, the focus will undoubtedly remain on its pioneering work with INT230-6 and the enduring quest to provide more effective cancer treatments. For further information about Intensity Therapeutics and their innovative approaches, one can explore their official website for the latest updates and research findings.